Chinese biopharma Hutchmed (HKEX:13; AIM: HCM) has announced that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate in adults with primary immune thrombocytopenia (ITP) in China.
Hutchmed is now planning a filing by the end of the year for sovleplenib in China, where it has been designated a Breakthrough Therapy.
The National Medical Products Administration of China (NMPA) granted the Breakthrough Therapy designation to sovleplenib for the indication studied in ESLIM-01 in January 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze